Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Leukemia, Myeloid, Acute 198Leukemia, Lymphocytic, Chronic, B-Cell 48Myelodysplastic Syndromes 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Recurrence 27Leukemia 26Lymphoma, Mantle-Cell 22Leukemia, Myelomonocytic, Chronic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Biphenotypic, Acute 15Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Burkitt Lymphoma 12Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasm, Residual 9Hematologic Neoplasms 9Multiple Myeloma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Waldenstrom Macroglobulinemia 5Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Leukemia, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Blast Crisis 4

Interventions

Dexamethasone 16Calcium Dobesilate 9Melphalan 6Lenalidomide 6Cyclophosphamide 5Bortezomib 5pomalidomide 3venetoclax 2daratumumab 2Thalidomide 2Doxycycline 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1belantamab mafodotin 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Interleukin-2 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1Hyaluronoglucosaminidase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Amyloidosis × venetoclax × Clear all
NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT03000660 2020-08-21

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Tufts Medical Center

Phase 1 Terminated
3 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡